- 
        
                             Eidos Therapeutics Inc. (EIDX $122.21) Eidos Therapeutics Inc. (EIDX $122.21)- $122.21 Cap: $4.72B
- View EIDX Profile
- View Questions on EIDX
 
Detailed Quote
                     Questions on this company?
                                    Become a Member
                                                            Company Profile
                    {tplLang.businessdescription | toLang tLang}
                                    { profileData.description }
                                    
{tplLang.details | toLang tLang}
{tplLang.ceo | toLang tLang}
                                    {profileData.profile.details.ceo}
                                    {tplLang.employees | toLang tLang}
                                    {profileData.profile.details.employees | numeraljs '0,0'}
                                    {tplLang.issuetype | toLang tLang}
                                    {profileData.profile.details.issuetype | asIssueType}
                                    {tplLang.industryclassifications | toLang tLang}
{tplLang.sector | toLang tLang}
                                    {profileData.profile.classification.sector}
                                    {tplLang.industry | toLang tLang}
                                    {profileData.profile.classification.industry}
                                    {tplLang.toolname| toLang tLang}
There is no {tplLang.toolname| toLang tLang} currently available for
                                            {data.symbolstring}.
                                    
                                    Interactive Chart
            Key Ratios
            Earnings
            Analyst Recommendations
                    5i Recent Questions
                            - 
        
                             BMO Laddered Preferred Share Index ETF (ZPR $12.07) BMO Laddered Preferred Share Index ETF (ZPR $12.07)- $12.07 P/E (TTM): 4.72X Cap: $1.44B
- View ZPR Profile
- View Questions on ZPR
 
- 
        
                             Global X Active Preferred Share ETF (HPR $10.26) Global X Active Preferred Share ETF (HPR $10.26)- $10.26 P/E (TTM): 8.17X Cap: $925M
- View HPR Profile
- View Questions on HPR
 
- 
        
                             iShares Global Real Estate Index ETF (CGR $30.79) iShares Global Real Estate Index ETF (CGR $30.79)- $30.79 P/E (TTM): 31.0X Cap: $257M
- View CGR Profile
- View Questions on CGR
 
- 
        
                             Vanguard Real Estate Index Fund ETF (VNQ $88.92) Vanguard Real Estate Index Fund ETF (VNQ $88.92)- $88.92 P/E (TTM): 33.61X Cap: $32.12B
- View VNQ Profile
- View Questions on VNQ
 
- 
        
                             iShares MSCI Mexico ETF (EWW $66.73) iShares MSCI Mexico ETF (EWW $66.73)- $66.73 P/E (TTM): 71.88X Cap: $2.08B
- View EWW Profile
- View Questions on EWW
 
- 
        
                             Invesco Preferred ETF (PGX $11.47) Invesco Preferred ETF (PGX $11.47)- $11.47 P/E (TTM): 6.5X Cap: $3.92B
- View PGX Profile
- View Questions on PGX
 
- 
        
                             iShares U.S. Preferred Stock (PFF $31.27) iShares U.S. Preferred Stock (PFF $31.27)- $31.27 P/E (TTM): 8.86X Cap: $14.53B
- View PFF Profile
- View Questions on PFF
 
- 
        
                             RBC Canadian Preferred Share ETF (RPF $23.95) RBC Canadian Preferred Share ETF (RPF $23.95)- $23.95 P/E (TTM): 8.3X Cap: $614M
- View RPF Profile
- View Questions on RPF
 
- 
        
                             Eidos Therapeutics Inc. (EIDX $122.21) Eidos Therapeutics Inc. (EIDX $122.21)- $122.21 Cap: $4.72B
- View EIDX Profile
- View Questions on EIDX
 
- 
        
                             iShares MSCI Brazil ETF (EWZ $31.08) iShares MSCI Brazil ETF (EWZ $31.08)- $31.08 P/E (TTM): 51.35X Cap: $6B
- View EWZ Profile
- View Questions on EWZ
 
- 
        
                             iShares MSCI Spain ETF (EWP $50.08) iShares MSCI Spain ETF (EWP $50.08)- $50.08 P/E (TTM): 45.11X Cap: $1.45B
- View EWP Profile
- View Questions on EWP
 
            Q: Hello, looking for emerging markets, ETFs you recommend ex China and ex India (as I already hold INDY and FXI).  Also looking for non-Canadian REIT ETF recommendations (I hold XRE). Finally what are your thoughts on preferred share ETFs and which would you recommend (Canadian or not) outside of CPD.
Thanks!
    Thanks!
- 
        
                             Eidos Therapeutics Inc. (EIDX $122.21) Eidos Therapeutics Inc. (EIDX $122.21)- $122.21 Cap: $4.72B
- View EIDX Profile
- View Questions on EIDX
 
            Q: Hi 5i team,
Thank you for your answer on Eidos Therapeutic on 21st, June. I own this stock and has gone up 30% + thanks to your positive comment ( at least the ceo has bought 28m in shares), I usually hold on to my winner and let it runs, but I do not understand why it gone up so fast within a short period of time with no news.
As stated in your answer, the company has no revenue and is still losing money. Do you see further upside for this stock ? Should I continue to hold ?
Thank you for your excellent service and helpful advice as always.
        
    Thank you for your answer on Eidos Therapeutic on 21st, June. I own this stock and has gone up 30% + thanks to your positive comment ( at least the ceo has bought 28m in shares), I usually hold on to my winner and let it runs, but I do not understand why it gone up so fast within a short period of time with no news.
As stated in your answer, the company has no revenue and is still losing money. Do you see further upside for this stock ? Should I continue to hold ?
Thank you for your excellent service and helpful advice as always.
- 
        
                             Eidos Therapeutics Inc. (EIDX $122.21) Eidos Therapeutics Inc. (EIDX $122.21)- $122.21 Cap: $4.72B
- View EIDX Profile
- View Questions on EIDX
 
            Q: Hi 5i Team,
Pls give your thought and outlook for Eidos Therapeutics.
Thank you for your excellent service as always.
    Pls give your thought and outlook for Eidos Therapeutics.
Thank you for your excellent service as always.
Insiders
                    Share Information
                    SEC Filings
                        News and Media
                     
                             
                             
                    